Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-07-28 , DOI: 10.1111/dom.14504
Ronald M Goldenberg ₁ , Vanita R Aroda ₂ , Liana K Billings ₃ , A Sia Louise Christiansen ₄ , Anders Meller Donatsky ₅ , Ehsan Parvaresh Rizi ₆ , Gracjan Podgorski ₇ , Katarina Raslova ₈ , David C Klonoff ₉ , Richard M Bergenstal ₁₀

Affiliation

LMC Diabetes and Endocrinology, Concord, Ontario, Canada.
Diabetes Clinical Research, Division of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Department of Medicine, NorthShore University HealthSystem/University of Chicago Pritzker School of Medicine, Skokie, Illinois, USA.
Biostatistics, Insulin & Devices, Novo Nordisk, Søborg, Denmark.
Medical & Science, New Generation Insulins, Novo Nordisk, Søborg, Denmark.
Global Medical Affairs, Novo Nordisk, Søborg, Denmark.
Internal Medicine, Greenacres Hospital, Port Elizabeth, South Africa.
Metabolic Center Ltd, Bratislava, Slovakia.
Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
International Diabetes Center and HealthPartners Institute, Minneapolis, MN, USA.

To compare time in range (TIR) with use of insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100) in people with type 2 diabetes.

中文翻译：